Skip to main content
Top
Published in: BMC Health Services Research 1/2013

Open Access 01-12-2013 | Research article

Case studies of innovative medical device companies from India: barriers and enablers to development

Authors: Szymon Jarosławski, Gayatri Saberwal

Published in: BMC Health Services Research | Issue 1/2013

Login to get access

Abstract

Background

Over 75% of the medical devices used in India are imported. Often, they are costly and maladapted to low-resource settings. We have prepared case studies of six firms in Bangalore that could contribute to solving this problem. They have developed (or are developing) innovative health care products and therefore are pioneers in the Indian health care sector, better known for its reverse engineering skills. We have sought to understand what enablers and barriers they encountered.

Methods

Information for the case studies was collected through semi-structured interviews. Initially, over 40 stakeholders of the diagnostics sector in India were interviewed to understand the sector. However the focus here is on the six featured companies. Further information was obtained from company material and other published resources.

Results

In all cases, product innovation has been enabled by close interaction with local medical practitioners, links to global science and technology and global regulatory requirements. The major challenges were the lack of guidance on product specifications from the national regulatory agency, paucity of institutionalized health care payers and lack of transparency and formalized Health Technology Assessment in coverage decision-making. The absence of national evidence-based guidelines and of compulsory continuous education for medical practitioners were key obstacles in accessing the poorly regulated and fragmented private market.

Conclusions

Innovative Indian companies would benefit from a strengthened capacity and interdisciplinary work culture of the national device regulatory body, institutionalized health care payers and medical councils and associations. Continuous medical education and national medical guidelines for medical practitioners would facilitate market access for innovative products.
Appendix
Available only for authorised users
Literature
1.
go back to reference Anonymous: Medical technology industry in India: riding the growth curve. 2010, Deloitte Anonymous: Medical technology industry in India: riding the growth curve. 2010, Deloitte
2.
go back to reference WHO: Medical devices: managing the mismatch. An outcome of the Priority Medical Devices project. 2011, World Health Organization WHO: Medical devices: managing the mismatch. An outcome of the Priority Medical Devices project. 2011, World Health Organization
3.
go back to reference Sahayog JS: Impressions from a rural laboratory. MFC Bull. 2006, 316-317. April-June:1–4 Sahayog JS: Impressions from a rural laboratory. MFC Bull. 2006, 316-317. April-June:1–4
4.
go back to reference Anonymous: Incentives and innovative financing for global health product development. 2010, The Global Health Technologies Coalition Anonymous: Incentives and innovative financing for global health product development. 2010, The Global Health Technologies Coalition
5.
go back to reference Anonymous: Innovative financing mechanisms for global health: overview and considerations for U.S. government participation. 2011, The Henry J. Kaiser Family Foundation Anonymous: Innovative financing mechanisms for global health: overview and considerations for U.S. government participation. 2011, The Henry J. Kaiser Family Foundation
6.
go back to reference Frost L, Reich M: ACCESS: how do good health technologies get to poor people in poor countries?. 2008, Cambridge, Massachusetts: Harvard Center for Population and Development Studies Frost L, Reich M: ACCESS: how do good health technologies get to poor people in poor countries?. 2008, Cambridge, Massachusetts: Harvard Center for Population and Development Studies
7.
go back to reference Moran M, Henderson K, Ropars AL, McDonald A, McSherry L, Wu L, Illmer A, Sturm T, Zmudzki F: G-FINDER. Neglected disease research and development: new times, new trends. 2009, Sydney, Australia: The George Institute for International Health Moran M, Henderson K, Ropars AL, McDonald A, McSherry L, Wu L, Illmer A, Sturm T, Zmudzki F: G-FINDER. Neglected disease research and development: new times, new trends. 2009, Sydney, Australia: The George Institute for International Health
8.
go back to reference Frew SE, Kettler HE, Singer PA: The Indian and Chinese health biotechnology industries: potential champions of global health?. Health Aff (Millwood). 2008, 27: 1029-1041. 10.1377/hlthaff.27.4.1029.CrossRef Frew SE, Kettler HE, Singer PA: The Indian and Chinese health biotechnology industries: potential champions of global health?. Health Aff (Millwood). 2008, 27: 1029-1041. 10.1377/hlthaff.27.4.1029.CrossRef
9.
go back to reference Henshall C, Mardhani-Bayne L, Fronsdal KB, Klemp M: Interactions between health technology assessment, coverage, and regulatory processes: emerging issues, goals, and opportunities. Int J Technol Assess Health Care. 2011, 27: 253-260. 10.1017/S0266462311000262.CrossRefPubMed Henshall C, Mardhani-Bayne L, Fronsdal KB, Klemp M: Interactions between health technology assessment, coverage, and regulatory processes: emerging issues, goals, and opportunities. Int J Technol Assess Health Care. 2011, 27: 253-260. 10.1017/S0266462311000262.CrossRefPubMed
10.
go back to reference Thatte U, Hussain S, de Rosas-Valera M, Malik MA: Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan. Value Health. 2009, 12 (Suppl 3): S18-S25.CrossRefPubMed Thatte U, Hussain S, de Rosas-Valera M, Malik MA: Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan. Value Health. 2009, 12 (Suppl 3): S18-S25.CrossRefPubMed
11.
go back to reference Anonymous: Eleventh Five Year Plan 2007–12. 2008, Planning Commission, Government of India Anonymous: Eleventh Five Year Plan 2007–12. 2008, Planning Commission, Government of India
12.
go back to reference Nandraj S: Beyond the law and the Lord: Quality of private health care. Econ Pol Wkly. 1994, 29: 1680-1685. Nandraj S: Beyond the law and the Lord: Quality of private health care. Econ Pol Wkly. 1994, 29: 1680-1685.
13.
go back to reference Das J, Hammer J: Money for nothing: The dire straits of medical practice in Delhi, India. J Development Economics. 2007, 83: 1-36. 10.1016/j.jdeveco.2006.05.004.CrossRef Das J, Hammer J: Money for nothing: The dire straits of medical practice in Delhi, India. J Development Economics. 2007, 83: 1-36. 10.1016/j.jdeveco.2006.05.004.CrossRef
14.
go back to reference Das J, Hammer J, Leonard K: The quality of medical advice in low-income countries. J Econ Perspect. 2008, 22: 93-114.CrossRefPubMed Das J, Hammer J, Leonard K: The quality of medical advice in low-income countries. J Econ Perspect. 2008, 22: 93-114.CrossRefPubMed
15.
go back to reference Kamunyori S, Al-Bader S, Sewankambo N, Singer PA, Daar AS: Science-based health innovation in Uganda: creative strategies for applying research to development. BMC Int Health Hum Rights. 2010, S5-10 Suppl 1 Kamunyori S, Al-Bader S, Sewankambo N, Singer PA, Daar AS: Science-based health innovation in Uganda: creative strategies for applying research to development. BMC Int Health Hum Rights. 2010, S5-10 Suppl 1
16.
go back to reference Chakma J, Masum H, Perampaladas K, Heys J, Singer PA: Case study: India’s billion dollar biotech. Nat Biotechnol. 2010, 28: 783-10.1038/nbt0810-783.CrossRefPubMed Chakma J, Masum H, Perampaladas K, Heys J, Singer PA: Case study: India’s billion dollar biotech. Nat Biotechnol. 2010, 28: 783-10.1038/nbt0810-783.CrossRefPubMed
17.
go back to reference Frew SE, Rezaie R, Sammut SM, Ray M, Daar AS, Singer PA: India’s health biotech sector at a crossroads. Nat Biotechnol. 2007, 25: 403-417. 10.1038/nbt0407-403.CrossRefPubMed Frew SE, Rezaie R, Sammut SM, Ray M, Daar AS, Singer PA: India’s health biotech sector at a crossroads. Nat Biotechnol. 2007, 25: 403-417. 10.1038/nbt0407-403.CrossRefPubMed
18.
19.
20.
go back to reference Engel N, Kenneth J, Pai M: TB diagnostics in India: creating an ecosystem for innovation. Expert Rev Mol Diagn. 12: 21-24. Engel N, Kenneth J, Pai M: TB diagnostics in India: creating an ecosystem for innovation. Expert Rev Mol Diagn. 12: 21-24.
21.
go back to reference Jarosławski S, Pai M: Why are inaccurate tuberculosis serological tests widely used in the Indian private healthcare sector? A root-cause analysis. J Epidemiol Global Health. 2012, 2: 39-50. 10.1016/j.jegh.2011.12.001. Available online 31 January 2012CrossRef Jarosławski S, Pai M: Why are inaccurate tuberculosis serological tests widely used in the Indian private healthcare sector? A root-cause analysis. J Epidemiol Global Health. 2012, 2: 39-50. 10.1016/j.jegh.2011.12.001. Available online 31 January 2012CrossRef
22.
go back to reference Bajaj R: It is time to wash the linen. The Natl Med J India. 2007, 20 (3): 147-149.PubMed Bajaj R: It is time to wash the linen. The Natl Med J India. 2007, 20 (3): 147-149.PubMed
23.
go back to reference Rajagopalan A: Misuse of diagnostic tests. Indian J Med Ethics. 2008, 5: 121-122.PubMed Rajagopalan A: Misuse of diagnostic tests. Indian J Med Ethics. 2008, 5: 121-122.PubMed
Metadata
Title
Case studies of innovative medical device companies from India: barriers and enablers to development
Authors
Szymon Jarosławski
Gayatri Saberwal
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2013
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/1472-6963-13-199

Other articles of this Issue 1/2013

BMC Health Services Research 1/2013 Go to the issue